• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Nutraceuticals for Men: Muscle Health and Performance Nutrition

    Aging in Place: Healthy Lifestyles Supplement Science-Based Solutions

    Getting an Edge in Esports: Meeting the Health Needs of Competitive Gamers

    Beyond CBD: Cannabis Compounds Warrant Recognition and More Research

    Leveling Out the Energy Segment for Mainstream, and Rethinking Caffeine
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    Bilberon Bilberry Extract Receives U.S. Patent For Eye Strain, Neck/Shoulder Pain

    Jordan Process Receives Nutrasource ICAP Certification for CBD

    FDA Warns About Steroids or Steroid-Like Substances in Bodybuilding Supplements

    Nootropics and Adaptogens Respond to Demand for Mind and Mood Support

    Sabinsa Honors 70th Anniversary of Diplomacy Between India and Japan
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    Bilberon Bilberry Extract Receives U.S. Patent For Eye Strain, Neck/Shoulder Pain

    Jordan Process Receives Nutrasource ICAP Certification for CBD

    Nootropics and Adaptogens Respond to Demand for Mind and Mood Support

    Sabinsa Honors 70th Anniversary of Diplomacy Between India and Japan

    Solvay Invests in Suanfarma’s Vanillin Production
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    Bilberon Bilberry Extract Receives U.S. Patent For Eye Strain, Neck/Shoulder Pain

    Jordan Process Receives Nutrasource ICAP Certification for CBD

    Senate Bill to Reauthorize FDA User Fees Includes Dietary Supplement Listing Provision

    FDA Warns About Steroids or Steroid-Like Substances in Bodybuilding Supplements

    Nootropics and Adaptogens Respond to Demand for Mind and Mood Support
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    Bilberon Bilberry Extract Receives U.S. Patent For Eye Strain, Neck/Shoulder Pain

    FDA Warns About Steroids or Steroid-Like Substances in Bodybuilding Supplements

    Nootropics and Adaptogens Respond to Demand for Mind and Mood Support

    Experts Debate Role of Supplements in Improving Public Health in EU

    GNC Adds Products from The Honest Company, Hers, and Womaness
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    Botanic Healthcare LLC

    Verdure Sciences

    PhytoGaia Inc

    Nutrition21, LLC

    Applied Food Sciences, Inc.
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Botanic Healthcare LLC

    Verdure Sciences

    PhytoGaia Inc

    Nutrition21, LLC

    Applied Food Sciences, Inc.
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    CBD in the Clinic: How Practitioners View Life After the Farm Bill

    Holistic, functional medicine practitioners see therapeutic value of CBD and have confidence in its efficacy for a range of common health concerns.

    CBD in the Clinic: How Practitioners View Life After the Farm Bill
    Related CONTENT
    • Sunflower Hemp Co
    • CRN: Clear Legal Plan & FDA Enforcement Can Ensure Safety & Benefits of CBD
    • Coalition Advocates for Declassification of Coconut as a ‘Tree Nut’ Allergen
    • Clearing Up Chaos in the Modern Nutraceuticals Market
    • CBD Regulatory Status Update: The Chaos Continues
    By Erik Goldman, Holistic Primary Care10.07.19
    Passage of the Farm Bill of 2018, and the concurrent FDA approval of Epidiolex—the first prescription drug derived from Cannabis sativa—were landmarks in the evolution of the market for cannabis and its popular derivative, cannabidiol (CBD).

    How are medical practitioners responding to these seismic changes? In Holistic Primary Care’s 2019 practitioner survey, we sought to find out.

    The survey—fielded last spring—included a suite of questions about CBD, cannabis, and hemp, and generated responses from 360 clinicians.

    Not surprisingly, the data indicated that CBD is very much a part of routine clinical practice in the world of holistic medicine, and that practitioners generally view it as effective.

    However, many expressed concerns about the influx of poorly made, spiked, or fraudulent products now flooding the market.

    At the same time, they’re also wary of the machinations of the pharmaceutical industry as it tries to stake its claims on cannabis therapeutics.

    A few quick demographics on the survey’s respondents: 32% are medical doctors, 15% are naturopaths, another 10% are osteopaths, 9% are nurses, and 7% are chiropractors. The remainder represented a wide range of practitioner sub-types, including acupuncturists, pharmacists, nutritionists, health coaches, and homeopaths.

    Nearly 70% are women, and the majority are in solo (49%) or small group (20%) practice settings.

    Nearly all (95%) take supplements and natural products for their own health, and 65% dispense products in their offices.

    Enthusiasm for CBD
    More than half of these practitioners—54% to be exact—currently recommend non-prescription CBD-containing products to their patients.

    Another 17% are using both prescription (Epidiolex) and non-prescription forms of CBD. However, none of our respondents are recommending prescription Epidiolex exclusively.

    An additional 15% indicated that while they are not currently recommending CBD to patients, they are considering it; 14% are not currently recommending and have no plans to do so.

    Notably, the conventionally-trained MDs in our cohort tracked very closely with the cohort as a whole in terms of their attitudes toward CBD.

    The top 10 conditions or disorders for which our practitioners are recommending CBD are as follows: chronic pain (86%); stress/anxiety (82%); insomnia/sleep problems (82%); low back pain (58%); headache (45%); depression (32%); GI problems (31%); menopausal Sx (22%); menstrual Sx (22%); multiple sclerosis (21%).

    Overall, they indicated that they find non-Rx CBD products to be effective for stress/anxiety (96%); insomnia & sleep problems (94%); chronic pain (94%); and headache (85%).

    The FDA’s approval of Epidiolex has had limited impact on our respondents’ views about the medical benefits of cannabis-based treatments. But that’s largely because most of them were already onboard with CBD and cannabis long before it became a pharmaceutical.

    More than two-thirds (69%) said they were already convinced of the therapeutic value of cannabis compounds prior to the approval of Epidiolex. Another 16% stated that while the approval did not thoroughly convince them of CBD’s medical value, they are now more willing to look at clinical research on CBD and other cannabinoids.

    And 13% said that approval of Epidiolex has made them more open to the medical value of cannabis.

    Impact of the Farm Bill
    Likewise, the 2018 Farm Bill—an historic piece of legislation widely lauded by industry as a legitimizing moment—has had limited, though significant, impact on holistic practitioners.

    More than half (52%) said they were already recommending hemp-derived medicines prior to passage of the Farm Bill last December. Another 24% indicated that the new law makes them more willing to recommend these products. In contrast, only 2% said they are less willing to recommend hemp products. Eighteen percent had no opinion about the Farm Bill.

    Given that HPC’s respondents are strongly self-identified as “holistic” or “functional” medicine practitioners, it’s not surprising that so many are already utilizing CBD in their clinics, or that the Epidiolex approval and the Farm Bill had limited impact on their attitudes.

    For the majority of our audience, cannabis and cannabis-derived substances needed no legitimization from governmental agencies. A cohort of more conservative mainstream doctors would probably have shown a different response pattern.

    Verbatim comments from our survey contained some valuable signals about the subtle but important ways the federal government’s moves are impacting day-to-day practice.

    One respondent wrote: “I was recommending (CBD) before. Since the passage of the Farm Bill I’m more comfortable carrying products in office.”

    Another suggested that the Farm Bill’s biggest impact may be on patients who’ve been curious but reluctant to try CBD.

    “The trickle-down effect is slow. I still have patients ‘fearful’ of hemp-based products, or working under government contracts prohibiting the use of any and all hemp-based products.”

    One thing is certain: our practitioners want more information about cannabis and CBD. This topic is tied with the microbiome for first place among subjects about which our readers most want to learn.

    Nearly two thirds (62%) of respondents indicated a desire for greater coverage of cannabis and CBD in Holistic Primary Care.

    Concerns About Over-Hype
    While our respondents generally view CBD as reliable and effective, some voiced a concern that the benefits are being over-hyped.

    “I am concerned Cannabis has been touted as a panacea. I’m sure it has benefits or it wouldn’t have been used for so many years. However, there are side effects and risks to everything, and these are not being considered or publicized carefully enough,” wrote one practitioner.

    Several others called for more research to substantiate the bold disease treatment and prevention claims or insinuations that have become prevalent in the marketplace, despite very clear FDA prohibitions against making such claims.

    There are other issues beyond product quality, unsubstantiated claims, and the potential for direct cannabis-associated adverse effects. One respondent pointed out that chronic, long-term use of CBD or other hemp-based substances may confound a practitioner’s ability to figure out what’s going on with a particular patient.

    “I find that the use of these products may obscure other clinical signs and progress, and interfere sometimes with the homeopathic medicines and the assessment of the response to them.”

    Wary of Big Pharma
    Many holistic practitioners—like many of their patients—are wary of the pharmaceutical industry. The Epidiolex approval struck many survey respondents as a brazen move on the part of Big Pharma to exploit an herb that it once vilified.

    A number of respondents voiced concern that the pharmaceutical-ization of cannabis will lead to higher prices, restriction of access, and ultimately exclusion of people who would potentially benefit from CBD and other cannabinoids.

    “Epidiolex is the pharma mafia’s fractionalized version of cannabis. What families with kids with epilepsy can afford $32,000 year and no insurance covering it? It is pure greed on big pharma’s part,” wrote one practitioner. “Cannabis is a vegetable and people should be able to grow their own!”

    There’s mistrust of the supplement industry as well. One respondent noted: “I am just as skeptical of nutraceutical companies as pharmaceutical companies. At least pharma has some regulation.”

    Isolates vs ‘Full Spectrum’
    Though the survey did not specifically include questions about preferences for CBD isolates compared to “full-spectrum” hemp oils, it is clear that this distinction is known to practitioners, and on the minds of some.

    “I think Epidiolex as a single CBD compound is Big Pharma’s way of getting in the Cannabis market and ignores the power of whole plant therapy.”

    But the reality is that, at this point in time, terms like “full-spectrum” and “whole-plant” are marketing language, not scientific definitions. No regulatory agency has published an official definition of “full spectrum” hemp.

    There’s a vague consensus within the supplement industry that the term signifies an extract of hemp leaves (not seeds) that contains a number of other naturally occurring cannabinoids in addition to CBD, but minimal levels of THC. But there’s no clear definition about which cannabinoids must be present in the “full spectrum” and in what quantity.

    Anthony Almada, a nutrition industry consultant who heads IMAGINutrition, noted that cannabis produces more than 1,000 unique chemicals, with more still to be characterized. Validated analytical methods have yet to be defined for most of the constituents of this plant.

    At most, the “full-spectrum” products currently on the market are testing for 30-40 chemical constituents.

    “They’re ‘full-spectrum’ by virtue of the limitations on what’s being tested,” Almada said at Holistic Primary Care’s 7th annual Practitioner Channel Forum.

    He likened hemp to wine grapes: one can predict the general chemical profile of a certain type of grape, but this profile changes depending on cultivation region, soil, weather conditions, harvesting and handling. The same is true for hemp, and really, for all herbs.

    This is one of the major distinctions between minimally processed herbal extracts, and highly purified single-constituent pharmaceuticals. Given the current state of regulations, CBD products blur that line: there’s the highly-purified prescription drug form (Epidiolex), and there are hundreds of products being sold as full-spectrum “CBD hemp oil” or variations of that wording.

    To varying degrees, CBD companies are insinuating therapeutic equivalence between their products and the prescription drug form. They often cite studies done with Epidiolex or other CBD isolates, to support their proposed benefits.

    Practitioners—especially those who have a lot of experience with cannabis—are aware of these distinctions. But their patients often are not, and this puts them in the position of having to educate their patients, and help them to separate the true signals from the noise.

    In general, Holistic Primary Care’s practitioner audience sees value in non-prescription CBD as a therapeutic tool. They have confidence in its efficacy for a range of common health concerns. It is up to the industry to continue earning that confidence, and to ensure that it is not betrayed. 


    Erik Goldman
    Holistic Primary Care

    Erik Goldman is co-founder and editor of Holistic Primary Care: News for Health & Healing, a quarterly medical publication reaching about 60,000 physicians and other healthcare professionals nationwide. He is also co-producer of the Practitioner Channel Forum, the nation’s leading conference focused on opportunities and challenges in the practitioner segment of the dietary supplement industry. 
    Related Searches
    • Testing
    • Regulatory
    • Analytical
    • Regulations
    Related Knowledge Center
    • Medical Nutrition
    • Dietary Supplements
    • Healthcare Trends
    Suggested For You
    Sunflower Hemp Co Sunflower Hemp Co
    CRN: Clear Legal Plan & FDA Enforcement Can Ensure Safety & Benefits of CBD CRN: Clear Legal Plan & FDA Enforcement Can Ensure Safety & Benefits of CBD
    Coalition Advocates for Declassification of Coconut as a ‘Tree Nut’ Allergen Coalition Advocates for Declassification of Coconut as a ‘Tree Nut’ Allergen
    Clearing Up Chaos in the Modern Nutraceuticals Market Clearing Up Chaos in the Modern Nutraceuticals Market
    CBD Regulatory Status Update: The Chaos Continues CBD Regulatory Status Update: The Chaos Continues
    Clinical Nutrition: A New Market Opportunity Clinical Nutrition: A New Market Opportunity
    The CBD Craze: Still Only the Beginning The CBD Craze: Still Only the Beginning
    Cannovia: Clearing Up CBD Market Confusion Cannovia: Clearing Up CBD Market Confusion
    Area Code 420 Has Arrived Area Code 420 Has Arrived
    Charlotte’s Web Introduces Hemp Extract-Infused Gummies Charlotte’s Web Introduces Hemp Extract-Infused Gummies
    EAS Assists Food & Hemp Firms with GRAS Submissions EAS Assists Food & Hemp Firms with GRAS Submissions
    Levagen PEA: A Legal Answer to CBD’s Issues Levagen PEA: A Legal Answer to CBD’s Issues
    Move Over Mainstream, Healthy Foods Are Here to Stay Move Over Mainstream, Healthy Foods Are Here to Stay
    Gencor Partners with Cannabis Researcher to Promote CBD Alternatives Gencor Partners with Cannabis Researcher to Promote CBD Alternatives
    BLIS M18 Probiotic Granted GRAS ‘No Objection’ Status BLIS M18 Probiotic Granted GRAS ‘No Objection’ Status

    Related Content

    • Sunflower Hemp Co

      ...
      Colby Terip, Owner 09.15.21

    • Breaking News | Herbs & Botanicals | Industry & Market News | Quality & Safety | Regulations
      CRN: Clear Legal Plan & FDA Enforcement Can Ensure Safety & Benefits of CBD

      CRN: Clear Legal Plan & FDA Enforcement Can Ensure Safety & Benefits of CBD

      Association implores FDA to exercise statutory discretion.
      09.23.19

    • Breaking News | Industry & Market News | Quality & Safety | Regulations | World Markets
      Coalition Advocates for Declassification of Coconut as a ‘Tree Nut’ Allergen

      Coalition Advocates for Declassification of Coconut as a ‘Tree Nut’ Allergen

      Despite FDA guidance on allergen labeling, botanically, coconut is a fruit not a nut.
      09.10.19


    • Dietary Supplements | Healthcare Trends
      Clearing Up Chaos in the Modern Nutraceuticals Market

      Clearing Up Chaos in the Modern Nutraceuticals Market

      Demand for novel, holistic wellness solutions has pushed the industry in new territory.
      By Sean Moloughney, Editor 09.09.19

    • Dietary Supplements | Herbs & Botanicals | Quality & Safety | Regulations
      CBD Regulatory Status Update: The Chaos Continues

      CBD Regulatory Status Update: The Chaos Continues

      FDA already has the authority to create a legal pathway for cannabidiol. It just needs the will to implement it.
      By Todd Harrison, Venable 09.09.19

      Trending
      • Vitamin D3, Omega-3s, Exercise May Cumulatively Reduce Cancer Risk In Older Adults | Nutraceuticals World
      • Leaven Essential To Launch Branded Botanical Extracts To Global Markets | Nutraceuticals World
      • Indena’s Meriva Curcumin Supplement May Benefit Kidney Function
      • Vitamin D3, Omega-3s, Exercise May Cumulatively Reduce Cancer Risk in Older Adults
      • Test On Hydrolyzed Collagen Shows Resoundingly High Bioavailability | Nutraceuticals World
      Breaking News
      • Bilberon Bilberry Extract Receives U.S. Patent For Eye Strain, Neck/Shoulder Pain
      • Jordan Process Receives Nutrasource ICAP Certification for CBD
      • FDA Warns About Steroids or Steroid-Like Substances in Bodybuilding Supplements
      • Nootropics and Adaptogens Respond to Demand for Mind and Mood Support
      • Sabinsa Honors 70th Anniversary of Diplomacy Between India and Japan
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Aging in Place: Lifestyle Supplements Science-Based Solutions
      • Getting an Edge in Esports: Meeting Health & Nutrition Needs
      • Nutraceuticals for Men: Muscle Health and Performance Nutrition

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Bilberon Bilberry Extract Receives U.S. Patent For Eye Strain, Neck/Shoulder Pain
      Jordan Process Receives Nutrasource ICAP Certification for CBD
      FDA Warns About Steroids or Steroid-Like Substances in Bodybuilding Supplements
      Coatings World

      Latest Breaking News From Coatings World

      Award for Sustainability: Evonik Receives EcoVadis Platinum Rating Again
      HMG Paints Gets Their Running Shoes On
      AGM Secures Exclusive Distribution Agreement with Indian Partner Imkemex
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Robocath Presents Results from R-Evolution Clinical Study
      Medtronic's Resolute Onyx Drug-Eluting Stent Shows Success for Left Main PCI
      Medtronic Shares 3-Year Renal Denervation Blood Pressure Trial Data
      Contract Pharma

      Latest Breaking News From Contract Pharma

      AGC Biologics Expands Capabilities at North America Campus
      Emergent CDMO Case Studies: Project Design & Implementation of Fill/Finish Technologies
      Aptar Pharma Launches HeroTracker Sense
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Mielle Organics Welcomes Steve Pamon to Advisory Board
      Makeup Revolution Expands into Walgreens
      Nu Skin Joins EcoBeautyScore Consortium
      Happi

      Latest Breaking News From Happi

      Revolution Beauty Expands Makeup Revolution Into Walgreens
      Barentz Develops Electronic Personal Care Product Guide
      P&G Temporarily Closes Downtown Cincinnati Office Due to Potential Security Concerns
      Ink World

      Latest Breaking News From Ink World

      Award for Sustainability: Evonik Receives Platinum Rating Again
      Nazdar Ink Technologies to Showcase Latest Ink Innovations at FESPA Global Print Expo 2022
      Epson Introduces First Direct-to-Fabric Printer for North America
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      In-Mold Decorating Association announces 2022 IMDA Awards Competition
      Essentra Packaging invests in Landa Nanographic press
      Nazdar to manufacture VFP electronic ink for US Market
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      'Right' Hygiene Conference to be Held in June
      Freudenberg to Present Battery Pack and Liquid Absorbers at Battery Show
      H&V Appoints Vice President and General Counsel
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Envista To Acquire Osteogenics
      Exactech Earns Breakthrough Status for JointMedica's Polymotion Hip Resurfacing
      Orthotic Brace Suppliers Convicted in $6.5M Fraud Scheme
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Wiliot Launches Battery-Assisted Version of its IoT Pixel Tags
      From Phygital to Virtual IDs
      Zebra Technologies Board Approves Additional $1 Billion Share Repurchase

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login